Scarica l'app Stockscreener
9.70
0.73%
0.07
Dopo l'orario di chiusura:
9.70
Daxor Corporation Borsa (DXR) Ultime notizie
[N-CEN/A] DAXOR CORP SEC Filing - Stock Titan
Insider Buying: Robert Michel Acquires Shares of Daxor Corp (DXR) - GuruFocus
Michel, Daxor CFO, buys $9,900 in DXR stock - Investing.com
Michel, Daxor CFO, buys $9,900 in DXR stock By Investing.com - Investing.com India
DAXOR CORP (DXR) CFO adds 1,000 shares in open-market buy - Stock Titan
DXR PE Ratio & Valuation, Is DXR Overvalued - Intellectia AI
Setup Watch: Will Daxor Corporation stock go up in YEARNew Guidance & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Earnings Risk: What is the target price for Daxor Corporation stock2026 Biggest Moves & High Accuracy Trade Alerts - baoquankhu1.vn
Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 - Bitget
Daxor’s Blood Volume Analysis Metric Validated as Uniquely - GlobeNewswire
Common leak scores stayed low while Daxor measured 20% hourly leak - Stock Titan
Daxor Corporation (NASDAQ:DXR) Short Interest Update - MarketBeat
Daxor (DXR) chief medical officer Jefferies acquires shares worth $0 - Investing.com
Daxor (DXR) chief medical officer Jefferies acquires shares worth $0 By Investing.com - Investing.com Australia
Daxor (DXR) CMO boosts stake with 5,941-share equity grant - Stock Titan
Macro Review: What is the long term forecast for Daxor Corporation stockEarnings Trend Report & Daily Price Action Insights - baoquankhu1.vn
Institution Moves: What is the earnings history of Daxor CorporationChart Signals & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Daxor Corporation to Showcase Next-Generation Portable - GlobeNewswire
Daxor to showcase next-gen portable BVA at ACC.26 session - TipRanks
Daxor (DXR) Showcases Innovative Blood Volume Analyzer at Major Cardiology Event - GuruFocus
Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26 - marketscreener.com
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions - marketscreener.com
[N-CEN] DAXOR CORP SEC Filing - Stock Titan
Daxor Details Portable FDA-Cleared Blood Volume Analyzer, 'Razor-and-Blades' Kit Growth at iAccess Alpha - MarketBeat
DXR: Direct blood volume analysis drives improved outcomes and rapid revenue growth in a vast market - TradingView
Daxor (DXR) Unveils Portable Blood Volume Analyzer at Critical C - GuruFocus
Daxor Corporation Showcases New Portable Blood Volume Analyzer - marketscreener.com
Daxor to debut portable blood volume analyzer at SCCM Critical Care Congress - TipRanks
ICU blood volume test linked to 66% fewer deaths goes portable - Stock Titan
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 - GlobeNewswire
Virtual investor conference to feature Daxor CEO’s 30-minute briefing - Stock Titan
Market Overview: Will Murano Global Investments Plc Equity Warrant benefit from rate cuts2026 Top Gainers & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
What analyst consensus says on Daxor Corporation stockExit Point & Fast Moving Trade Plans - Naître et grandir
Layoff Watch: Is Daxor Corporation a turnaround storyGap Up & Safe Entry Trade Reports - baoquankhu1.vn
Daxor (NYSEAMERICAN:DXR) Share Price Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
European Stocks Set for Mixed Opening Amid Geopolitical Tensions - Intellectia AI
DXR SEC FilingsDAXOR CORP 10-K, 10-Q, 8-K Forms - Stock Titan
Daxor Corporation Reports 2025 Fiscal Year Results, Operating Revenue Up 45%, Net Asset Value Rises to $9.07 per Share - marketscreener.com
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - Bitget
Daxor reports 45% revenue growth, plans regulatory shift - Investing.com
Daxor Corporation CEO and President Michael Feldschuh provides corporate update in letter to shareholders - marketscreener.com
Daxor (DXR) Records Strong Growth and Regulatory Changes in 2025 - GuruFocus
Daxor issues update in Letter to Shareholders - TipRanks
Daxor (DXR) Secures FDA Clearance for Advanced Blood Volume Anal - GuruFocus
Daxor Corporation CEO And President Michael Feldschuh Provides Corporate Update In Letter To Shareholders - TradingView
7-pound blood volume analyzer wins FDA clearance, gains hospital users - Stock Titan
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share - marketscreener.com
Daxor Corporation Reports 2025 Fiscal Year Results: - GlobeNewswire
DXR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
FDA‑cleared BVA boosts momentum; Daxor (NASDAQ: DXR) posts NAV $9.07 and $46M operating valuation - Stock Titan
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Interest in Daxor Corporation (NASDAQ:DXR) Decreases By 44.0% - MarketBeat
Daxor Corporation (DXR) Competitors - Meyka
Daxor (NASDAQ:DXR) vs. Addus HomeCare (NASDAQ:ADUS) Financial Survey - Defense World
EBIT per share of Daxor Corporation – NASDAQ:DXR - TradingView
Daxor (NYSEAMERICAN:DXR) Share Price Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
1.21%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):